Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 16.
doi: 10.1007/s15010-025-02584-y. Online ahead of print.

Carbapenemase type and mortality in blood-stream infections caused by carbapenemase-producing enterobacterales: a multicenter retrospective cohort study

Yaakov Dickstein  1 , Dafna Yahav  2   3 , Giusy Tiseo  4 , Cristina Mussini  5 , Erica Franceschini  6 , Antonella Santoro  6 , Galia Rahav  7   8 , Hila Elinav  9   10 , Assaf Potruch  10   11 , Amir Nutman  8   12 , Mical Paul  1   13 , Marco Falcone  4
Affiliations

Carbapenemase type and mortality in blood-stream infections caused by carbapenemase-producing enterobacterales: a multicenter retrospective cohort study

Yaakov Dickstein et al. Infection. .

Abstract

Background: Previous studies analyzing differences in mortality associated with carbapenemase type in patients with a variety of infections caused by carbapenemase-producing Enterobacterales (CPE) have produced conflicting results.

Methods: We performed a multinational multicenter retrospective cohort study. Adult patients with blood-stream infections (BSI) caused by CPE between 2015 and 2020 were included. The primary outcome was 14-day mortality; 28-day mortality and microbiological failure were secondary outcomes. Clinical and microbiological data were collected and analyzed using conditional logistic regression.

Results: A total of 360 patients were identified of whom 226 had infections caused by KPC-producing isolates, 109 by NDM-producing isolates and 25 by other carbapenemases. Definitive therapy was colistin-based in 35.1% of patients, ceftazidime/avibactam ± aztreonam (CAZ/AVI ± A) in 28.2% and other in 23.4%. Overall 14-day mortality was 28.1%; carbapenemase type was unassociated with mortality in univariate or multivariate analyses. Antimicrobial therapy was significantly associated with 14-day mortality: patients treated with CAZ/AVI ± A had an adjusted hazard ratio of 0.172 (95% confidence interval 0.063-0.473) for death as compared to patients treated with colistin-based therapy. At 28 days, overall mortality was 35.3%; no association was observed between carbapenemase type and 28-day mortality or microbiological failure.

Conclusion: After controlling for antimicrobial therapy, we did not find evidence of an association between carbapenemase type and mortality. Ceftazidime/avibactam was associated with a greater than 80% reduction in mortality as compared with colistin.

Keywords: Aztreonam; Blood-stream infection; CPE; Ceftazidime-avibactam; Colistin; KPC; NDM.

Plain language summary

We analyzed differences in mortality associated with different carbapenemase types in patients with infections caused by carbapenemase-producing Enterobacterales. No evidence of an association was found, however therapy with ceftazidime/avibactam was associated with a reduction in mortality as compared with colistin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no conflict of interest.

References

    1. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–803. - DOI
    1. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh P, Viale P, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–34. - DOI
    1. Seo H, Kim HJ, Kim MJ, Chong YP, Kim SH, et al. Comparison of clinical outcomes of patients infected with KPC- and NDM-producing enterobacterales: a retrospective cohort study. Clin Microbiol Infect. 2021;27(8):1167.e1-1167.e8. - DOI
    1. Dickstein Y, Solter E, Schwartz D, Nutman A, Harevrich I, et al. The Israeli National policy for discontinuation of isolation of carbapenem-resistant enterobacterales carriers by carbapenemase type: a retrospective cohort study. Clin Microbiol Infect. 2021;27(10):e15181–3. - DOI
    1. Pudpong K, Pattharachayakul S, Santimaleeworagun W, Nwabor OF, Laohaprertthisan V, et al. Association between types of carbapenemase and clinical outcomes of infection due to carbapenem resistance enterobacterales. Infect Drug Resist. 2022;15:3025–37. - DOI - PMC

LinkOut - more resources